This approval is another example of the benefits of our agency's orphan drugs program, which seeks to answer the medical needs of small groups of patients. The doctors who perform approximately 2,200 heart transplants in the U.S. each year will now have a new option for enhancing successful outcomes by preventing the rejection of the grafted organs.
| |